These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23578555)

  • 1. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma.
    Xu Q; Leong J; Chua QY; Chi YT; Chow PK; Pack DW; Wang CH
    Biomaterials; 2013 Jul; 34(21):5149-62. PubMed ID: 23578555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monodisperse double-walled microspheres loaded with chitosan-p53 nanoparticles and doxorubicin for combined gene therapy and chemotherapy.
    Xu Q; Xia Y; Wang CH; Pack DW
    J Control Release; 2012 Oct; 163(2):130-5. PubMed ID: 22981564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy.
    Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y
    Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma.
    Chen CA; Lo CK; Lin BL; Sibley E; Tang SC
    Cancer Biol Ther; 2008 Feb; 7(2):303-9. PubMed ID: 18059187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Abo Mansour HE; El-Batsh MM; Badawy NS; Mehanna ET; Mesbah NM; Abo-Elmatty DM
    Hum Exp Toxicol; 2020 Nov; 39(11):1528-1544. PubMed ID: 32519553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4883-4894. PubMed ID: 38165424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
    Chen D; Pan X; Xie F; Lu Y; Zou H; Yin C; Zhang Y; Gao J
    Int J Nanomedicine; 2018; 13():6855-6870. PubMed ID: 30498347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway.
    Ye BL; Zheng R; Ruan XJ; Zheng ZH; Cai HJ
    Biochem Biophys Res Commun; 2018 Jan; 495(1):414-420. PubMed ID: 29097204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
    Wiradharma N; Tong YW; Yang YY
    Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SP94-Targeted Triblock Copolymer Nanoparticle Delivers Thymidine Kinase-p53-Nitroreductase Triple Therapeutic Gene and Restores Anticancer Function against Hepatocellular Carcinoma in Vivo.
    Sukumar UK; Rajendran JCB; Gambhir SS; Massoud TF; Paulmurugan R
    ACS Appl Mater Interfaces; 2020 Mar; 12(10):11307-11319. PubMed ID: 32048820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
    Nasr M; Nafee N; Saad H; Kazem A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
    Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
    Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and application of micro-polysaccharide drug carriers incorporating doxorubicin and superparamagnetic iron oxide for bimodality treatment of hepatocellular carcinoma.
    Tang SL; Bai MY; Wang JY; Hong PD
    Colloids Surf B Biointerfaces; 2017 Mar; 151():304-313. PubMed ID: 28040662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of intracellular reduction-sensitive amphiphilic polyethyleneimine and poly(ε-caprolactone) graft copolymer for on-demand release of doxorubicin and p53 plasmid DNA.
    Davoodi P; Srinivasan MP; Wang CH
    Acta Biomater; 2016 Jul; 39():79-93. PubMed ID: 27154500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor.
    Lee SY; Choi JW; Lee JY; Kim DD; Kim HC; Cho HJ
    Drug Deliv; 2018 Nov; 25(1):1472-1483. PubMed ID: 29909706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
    Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma.
    Li J; Zhang Y; Cai C; Rong X; Shao M; Li J; Yang C; Yu G
    Biomater Sci; 2020 Jan; 8(1):189-200. PubMed ID: 31821399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH-responsive self-healing injectable hydrogel based on N-carboxyethyl chitosan for hepatocellular carcinoma therapy.
    Qu J; Zhao X; Ma PX; Guo B
    Acta Biomater; 2017 Aug; 58():168-180. PubMed ID: 28583902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.